Canada Pension Plan Investment Board
SYRE icon

Canada Pension Plan Investment Board’s Spyre Therapeutics SYRE Stock Holding History

Canada Pension Plan Investment Board’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-200
Closed -$37K – 1622
2018
Q4 		$37K Buy
+200
New +$42.4K ﹤0.01% 1214

Other funds holding SYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Canada Pension Plan Investment Board's SYRE Position: Q1 2019 in Review

Canada Pension Plan Investment Board sold out of Spyre Therapeutics (SYRE) in Q1 2019, closing a stake of 200 shares — an estimated $37K sold.

Canada Pension Plan Investment Board first reported a position in SYRE in Q4 2018 and held it in 1 quarter. The position peaked at $37K in Q4 2018. 71 funds tracked by Wall St. Rank hold SYRE as of Q1 2019.

  • Canada Pension Plan Investment Board reported no remaining Spyre Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Canada Pension Plan Investment Board sold 200 Spyre Therapeutics shares in Q1 2019, an estimated $37K.
  • Canada Pension Plan Investment Board first reported a position in Spyre Therapeutics in Q4 2018 and held it in 1 quarter.
  • Canada Pension Plan Investment Board's Spyre Therapeutics position peaked at $37K in Q4 2018.
  • 71 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2019.

Based on Canada Pension Plan Investment Board's 13F filing for Q1 2019, filed 15 May 2019.